Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALL

Video

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

Ching-Hon Pui, MD, chair, Oncology Department, St. Jude Children's Research Hospital, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia (ALL).

CAR T-cell therapy is currently used in pediatric patients with relapsed/refractory ALL. Increasingly, it is used to treat patients with central nervous system relapsed or testicular relapse, says Pui.

In the past, pediatric patients with ALL required radiation to be cured; however, now CAR T-cell therapy can cure those patients without the use of radiation. Pui believes that in the near future, CAR T-cell therapy will be used to treat patients with high-risk ALL and avoid intensive chemotherapy altogether, improving the patient's quality of life as well as the cure rate.

Recent Videos
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Related Content
© 2025 MJH Life Sciences

All rights reserved.